Advances in genomic medicine are playing an increasingly important role in the field of cardiology. Better analysis and understanding of patient genomic and epigenomic information can enable more personalised patient treatment and medical intervention. Here, Professor John Giannios considers the potential to use genomic medicine to prevent, monitor, diagnose and…
List view / Grid view
Having identified the histone demethylase KDM5A as a multiple myeloma target, researchers developed a KDM5 inhibitor to treat the cancer.
Researchers have used CRISPR to create a new technology that can switch off almost any gene in cells, called CRISPRoff.
New research shows tissue damage to cells carrying KRAS mutations induces epigenetic changes that promote pancreatic cancer.
A new study has revealed a range of genomic, proteomic and transcriptomic data about head and neck cancers, presenting possible treatment strategies.
Researchers have analysed 750 samples from patients with SARS-CoV-2 to discover details about its transmission and mutational properties.
The new approach enables researchers to isolate brain cells associated with Parkinson's disease and study their gene expression patterns.
New findings suggest that late-onset Alzheimer's Disease (AD) is driven by epigenetic changes in the brain.
Researchers found increasing levels of Dnmt3a2 in neurons activated at the time of making a memory, improved its recall in mice.
A new microfluidic technology has been developed which can profile histone modifications with as few as 100 cells per assay.
A new paper describes the first full study of the epigenetics of human tumour organoids, suggesting this could be used to develop novel oncology treatments.
Scientists have showed that a three inhibitors (3i) cocktail could reprogramme fibroblasts to a naïve embryonic stem cell-like state and remove disease-associated epigenetic changes.
Researchers have shown that two epigenetic regulators could be targeted to improve cognitive and behavioural decline in age-related diseases like Alzheimer’s.
A murine study found histone deacetylase 3 (HDAC3) inhibitors reverse epigenetic changes caused by CREBBP mutations found in lymphomas and could be developed into a novel therapy.